Zentiva Plans Initial Public Offering
Prague - The Czech generics pharmaceutical company Zentiva a.s. intends to seek a listing on the Prague and London Stock Exchanges through a global offering of shares and GDRs (Global Depositary Receipts). The shares are being offered in the Czech Republic. In the United States and elsewhere outside the Czech Republic shares and GDRs are only being offered to certain institutional investors. Merrill Lynch International has been appointed global co-ordinator, sole book runner and lead manager to the offer.
“We are delighted that Zentiva is to become a public company by being the first company to undertake a significant IPO on the Prague Stock Exchange. The offering will facilitate our strategy of expansion into
other key Central and Eastern European markets,” said Jiri Michal, chairman of the board and CEO of Zentiva. The company develops, manufactures and markets branded generic pharmaceutical products. It is one of the largest pharmaceutical companies in the region and on a combined basis the largest generic pharmaceutical supplier in its four core markets of the Czech Republic, Slovakia, Poland and Russia.
In August 2003, Zentiva increased its critical mass in Slovakia, Poland and Russia with the acquisition of Slovakia's largest generic player Slovakofarma. The former Leciva and Slovakofarma now market their pharmaceutical products under the name Zentiva in all markets. Based on IMS data Zentiva's market share by value for generic pharmaceutical products amounts to 51% in the Czech Republic and to 61% in Slovakia.